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The aim of this study was to assess the safety and efficacy of biweekly irinotecan plus leucovorin-modulated 5-fluorouracil i.v. bolus in
metastatic colorectal carcinoma according to the age of patients. For this purpose, we have analysed 108 patients randomly allocated
to receive irinotecan 200mgm
 2 i.v. (1-h infusion) on day 1, and L-leucovorin 250mgm
 2 i.v. (1-h infusion) plus 5-fluorouracil
850mgm
 2 i.v. bolus on day 2 every 2 weeks (IRIFAFU) in our previous SICOG 9801 trial. According to age, patients were
retrospectively divided into three groups: younger (p54 years, n¼37), middle-aged (55–69 years, n¼64), and elderly (X70 years,
n¼17). Apart from gender, pretreatment characteristics were well balanced across the three groups. WHO grade X3 neutropenia
and diarrhoea affected on the whole 46 and 16 patients, respectively, without any significant difference according to age-grouping.
Patients aged p54 years stayed on therapy for a longer time (median 24 vs 14–15 weeks), and received more cycles (median 9 vs 7),
than the older ones. Only one patient in the young group withdrew consent to therapy as opposed to four patients each in the aged
and elderly one. Response rate was 38% for younger patients, 34% for aged, and 35% for the elderly ones. Median time to
progression was 7.4, 8.0, and 5.3 months, and median survival time was 13.4, 15.3, and 13.9 months, respectively. We conclude that
IRIFAFU given every other week may represent a suitable therapeutic option also for elderly patients with metastatic colorectal
carcinoma.
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Colorectal carcinoma is among the most common cancers in
western countries. In Italy, about 40 new cases per 100000 males,
and 20 new cases per 100000 females are diagnosed each year
(Zanetti et al, 1997). Most of these cases are discovered in patients
aged 65 years or more.
In recent years, the postsurgical administration of 5-fluorouracil
(FU)-based chemotherapy in high-risk (Dukes’ stage C) colon
cancer patients has been proven to reduce the recurrence and
death rate (Wolmark et al, 1999). On the contrary, there is still no
agreement about the absolute benefit that could be obtained in
patients with more limited (Dukes’ stage B) extension (Interna-
tional Multicenter Pooled Analysis of B2 Colon Cancer Trials,
1999; Mamounas et al, 1999). Anyway, recently published retro-
spective studies and meta-analyses have reported no interaction
between age of patients and effect of adjuvant chemotherapy,
suggesting that elderly patients should also be offered such
treatments (Sargent et al, 2001a; Sundararajan et al, 2002).
Until recently, the usual management for the recurrent or
metastatic disease included leucovorin (LV)-modulated FU che-
motherapy (LV-FU), given in a 5-day monthly or in a once-a-week
schedule (Buroker et al, 1994). These two regimens produced
equivalent results, and a meta-analysis has shown that this
palliative treatment was associated with a 35% reduction in the
risk of death as compared with supportive care alone, which
translated in an improvement in median survival of 3.7 months
(Colorectal Cancer Collaborative Group, 2000). Also in this case,
no age-related difference was found as to the effectiveness of
chemotherapy (Chiara et al, 1998; Popescu et al, 1999).
Despite this observation, the number of elderly patients
receiving palliative chemotherapy for colorectal carcinoma is still
limited (Hutchins et al, 1999). Indeed, there is still a diffuse
concern about the compliance and tolerability of chemotherapy in
such patients (Daniele et al, 1999). On the other hand, some
investigators have already stressed that performance status, and
associated morbidities, more than age of patients, may adversely
affect their outcome (Extermann et al, 1998; Yancik et al, 2001).
Recently, novel drugs such as irinotecan or oxaliplatin have
shown activity in this disease when used either alone or in Received 16 October 2002; revised 3 June 2003; accepted 29 June 2003
*Correspondence: Dr P Comella; E-mail: pasqualecomella@libero.it
British Journal of Cancer (2003) 89, 992–996
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
C
l
i
n
i
c
a
lcombination with FU. Addition of irinotecan to LV-FU has been
proven to increase significantly the response rate, the time to
progression, and the median survival of patients, in comparison
with LV-FU alone (Douillard et al, 2000; Saltz et al, 2000). Also,
oxaliplatin combined with LV-FU has demonstrated to increase
significantly the response rate and the time to progression, but not
the survival, in comparison with the same regimen without
oxaliplatin (de Gramont et al, 2000). Therefore, irinotecan plus LV
and FU is now considered the gold standard of treatment for
metastatic patients. However, because no prospective analysis has
been carried out on the tolerability of these new combinations in
aged people, a special care has been recommended, in considera-
tion of the early and unpredictable adverse events that may
occur in older individuals (Rothemberg et al, 2001; Sargent et al,
2001b).
In recent years, the Southern Italy Cooperative Oncology Group
(SICOG) has devised an original biweekly regimen, including
irinotecan plus LV-modulated FU given as i.v. bolus (IRIFAFU) for
metastatic colon cancer patients (Comella et al, 2000). The
IRIFAFU combination has been compared in a randomised
multicentre study (SICOG trial 9801) with FU modulated by
methotrexate and LV. In that trial, the IRIFAFU regimen produced
a greater response rate, and a longer time to progression, than the
control treatment (Comella et al, 2002). Here we report the results
of a retrospective analysis we have carried out on the patients
randomly allocated to receive the combination regimen, with the
aim of having a deeper insight on the interaction between age of
patients, their tolerability to chemotherapy, and outcome.
PATIENTS AND METHODS
Patient population
Patients affected by metastatic colorectal cancer, enrolled into the
SICOG trial 9801, and randomly allocated to receive the IRIFAFU
regimen (experimental arm), were the object of this retrospective
analysis. Briefly, eligibility criteria for SICOG trial 9801 were:
histologically proven adenocarcinoma of the colon or rectum;
presence of bidimensionally measurable lesion(s); age X18 years;
performance status p2 of the Eastern Cooperative Oncology
Group (ECOG) scale; adequate liver, renal, and bone marrow
reserve. Patients previously treated with FU-based adjuvant
chemotherapy were also included, provided that at least 6 months
had elapsed from treatment discontinuation.
Treatment
Patients in the experimental arm received the IRIFAFU regimen:
irinotecan 200mgm
 2 given i.v. over 1-h on day 1, and L-
leucovorin 250mgm
 2 given as 1-h i.v. infusion, followed by FU
850mgm
 2 as i.v. bolus, on day 2. Cycles were repeated every
other week until progression, or for a maximum of 6 months.
Attending physicians were required to specify the reason for an
earlier treatment discontinuation. Disease status was checked
every 2 months, and classified according to the World Health
Organization (WHO) criteria (Miller et al, 1981). Adverse events of
each treatment cycle were scored according to WHO scale (Miller
et al, 1981), and the worst grade for each patient during treatment
was recorded. Haematological toxicity was checked weekly. The
actual dose intensity of cytotoxic drugs over 4 and 8 cycles (DI4
and DI8, respectively) was calculated as previously reported.
Patients were followed every 2 months for assessing tumour
progression and survival, and the cause of death (disease- or
treatment-related, or due to other reasons) was recorded.
Analysis of safety and activity
According to their age, patients were divided into three groups:
younger (p54 years), middle-aged (55–69 years), and elderly
(X70 years). Differences in distribution of pretreatment char-
acteristics among the three groups were assessed by the w
2 test.
Comparison of treatment in the three age groups (i.e., number of
cycles, duration of therapy, and dose intensities) was made by the
Kruskal–Wallis test. The difference in reasons for going off-study
was assessed for significance by the Pearson w
2-test. For exploring
the interaction between pretreatment characteristics and treatment
activity, patients achieving a complete or partial response were
classified as ‘responders’, while patients showing a stable or
progressive disease, as well as those not assessed for response,
were classified as ‘failures’ according to intent-to-treat analysis.
The following characteristics were explored for correlation with
activity: age, sex, primary site, previous radical surgery, previous
adjuvant chemotherapy, time to occurrence of metastatic disease,
performance status, presence of symptoms, significant loss of body
weight, number of disease sites, and basal carcinoembryonic
antigen (CEA) serum level. For statistical analysis, the following
variables were coded as dichotomous: primary site (colon or
rectum), performance status (0 or X1), timing of metastasis
(synchronous or metachronous), number of disease sites (1 or
X2), and CEA basal value (o100 or X100ngml
 1).
Analysis of outcome
Progression-free survival (PFS) was calculated for each patient
from the date of registration to the date of documented tumour
progression, or death. Patients who discontinued the treatment
early because of toxicity, refusal, or reason other than progression,
were considered as censored at that time interval. Overall survival
(OS) time was calculated for all patients from the date of
registration to the date of death for any cause, or to patients last
follow-up. Survival curves were generated by actuarial method
(Kaplan and Meier, 1958), and compared by the log-rank test (Peto
et al, 1977).
A logistic regression analysis was performed to identify the
interaction between probability of response and pretreatment
characteristics, while the Cox multivariate analysis (Cox, 1972)
was carried out to assess their effect on time to progression and
survival.
RESULTS
Patients and treatment
Patient main characteristics are listed in Table 1, according to age
grouping. An imbalance in gender distribution was observed,
given that elderly patients were more likely to be male (P¼0.004).
Other baseline characteristics were well matched across the three
groups.
Younger patients stayed somewhat longer on treatment, while a
similar length of treatment (and number of cycles) was
administered to middle-aged or elderly patients (Table 2). Analysis
of reasons for treatment discontinuation revealed that younger
patients were less likely to refuse chemotherapy as compared to the
middle-aged or elderly ones (P¼0.016), while other causes were
evenly distributed among the three groups.
A greater (although not statistically significant) proportion of
elderly patients (35%) had a dose reduction along the first four
cycles, in comparison with the middle-aged (25%), and younger
patients (19%). In addition, a 42-week delay during the
administration of the first four cycles was applied in 40% of
elderly, in 25% of middle-aged, and in 26% of younger patients.
During the four subsequent cycles, such a delay was applied in 62%
of elderly, in 64% of middle-aged, and in 65% of younger patients.
As a consequence, the median DI4 of cytotoxic drugs was slightly
lower for elderly patients, but DI8 was substantially comparable in
all groups (Table 3).
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lAfter discontinuation of study treatment, 55 patients (47% of the
whole series) received second-line therapy: 19 (51%) younger
patients, 28 (44%) middle-aged patients, and 7 (41%) elderly
patients (w
2 for trend not significant).
Safety
Main severe haematological toxicity of this regimen was neutro-
penia, which occurred in 46 patients on the whole: grade X3
neutropenia was detected in 43% of younger, in 41% of middle-
aged, and in 31% of elderly group. Only four patients suffered from
neutropenic fever or infection: their age ranged between 45 and 64
years. Among nonhaematological side effects, grade X3 diarrhoea
was reported in 11% of younger, 18% of aged, and 6% of elderly
patients (w
2-test not significant). Severe stomatitis occurred in
three patients on the whole: one patient in each age-group.
Occurrence of other adverse events was not different in the three
age groups (Table 4). Interestingly, a lower proportion of elderly
patients suffered from at least one episode of grade X3 toxicity of
any type (excluding alopecia) in comparison with aged or younger
patients. However, seven patients, all belonging to the middle-aged
group, went off-study for toxicity (diarrhoea, six cases; severe bone
marrow suppression, one case). Treatment-induced or treatment-
exacerbated early death (as defined by Rothemberg et al, 2001)
occurred in three of 118 (2.5%) patients: a 62-year-old woman,
completely asymptomatic at study entry), died of severe diarrhoea
and dehydration after two courses; another woman, aged 63 years,
and with initial PS¼1, suffered from deep phlebitis with
subsequent pulmonary embolism and acute cardiac failure after
three cycles; and a 69-year-old man, entered into the study in good
PS and no cardiac contraindications, had a fatal myocardial
infarction after three cycles.
Table 1 Main patient characteristics according to age grouping
Age groups (years)
Characteristics
p54
n¼37
55–69
n¼64
X70
n¼17
Total
N¼118
Median age in years (range) 48 (28–54) 64 (55–69) 68 (65–79) 62 (28–79)
Males 14 41 14 69
Females 23 23 3 49
Primary
Colon or recto–sigmoid 27 48 13 88
Rectum 10 16 4 30
Previous surgery
No 5 11 1 17
Yes 32 53 16 101
Previous adjuvant CT
No 26 50 13 89
Yes 11 14 4 29
Synchronous metastasis
No 18 28 9 55
Yes 19 36 8 63
Performance status
0 2 03 81 27 0
11 5 2 4 5 4 4
22 2 0 4
Presence of symptoms
No 20 43 13 76
Yes 17 21 4 42
Weight loss X5%
No 28 53 12 93
Yes 9 11 5 25
No. disease sites
1 2 03 61 06 6
411 7 2 8 7 5 2
Liver involvement
No 12 14 8 34
Yes 25 50 9 84
Single 4 12 0 16
o25% 12 23 4 39
425% 9 15 5 29
Lung involvement
No 31 49 13 93
Yes 6 15 4 25
CEA basal value X100
No 24 42 11 85a
Yes 11 22 6 20a
aNo available basal values in 13 patients.
Table 2 Duration of treatment, number of delivered cycles, and reason
for discontinuation of therapy according to age grouping
Age groups (years)
p54
n¼37
55–69
n¼64
X70
n¼17
Stay on treatment (weeks)
Median 24 15 14 P
a¼0.091
Range 2–42 2–45 2–35
Administered cycles
Median 9 7 7 P
a¼0.045
Range 2–16 1–20 1–12
Reasons for treatment
discontinuation:
As for protocol 32 40 13
Toxicity 0 7 0
Refusal 1 4 4 P
b¼0.016
Disease complications 1 5 0
Death 0 5 0
Physician’s decision 3 3 0
aKruskal–Wallis test.
bPearson’s w
2 test.
Table 3 Absolute dose intensity (mgm
 2week
 1) over the first four
(DI4) and eight (DI8) cycles according to age grouping
Age–groups (years)
Dose intensity p54 n¼37 55–69 n¼64 X70 n¼17 P
a
DI4
IRI
Median 86 82 66 0.230
Range 55–100 52–100 41–100
5FU
Median 366 361 270 0.131
Range 231–425 249–458 175–426
DI8
IRI
Median 85 75 81 0.532
Range 58–98 50–100 50–100
5FU
Median 366 322 345 0.449
Range 230–410 230–41 209–425
aKruskal–Wallis test.
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As already reported, the IRIFAFU regimen produced nine
complete plus 33 partial responses, for an overall response rate
(RR) of 36% (95% confidence interval, 28–44%), according to
intent-to-treat analysis. In addition, 12 patients showed a tumour
shrinkage that did not qualify for a major response. RR was
comparable in all age groups: it was 38% in the younger, 34% in
the middle-aged, and 35% in the elderly patients. Similarly, no
statistically significant difference in RR was observed according to
gender (males, 36%; females, 35%); primary site (colon, 37%;
rectum, 30%); previous adjuvant chemotherapy (yes, 41%; no,
34%); onset of metastasis (synchronous, 35%, metachronous,
36%); basal CEA serum level (o100ngml
 1, 36%; X100ngml
 1,
40%). Some baseline characteristics, although not reaching a
significant P-value, seemed affecting more the probability of
response. This holds true for number of disease sites (single, 42%;
multiple, 27%), performance status (0, 41%; X1, 27%), disease
symptoms (absent, 41%; present, 26%), previous loss of body
weight (absent, 39%; present, 24%), previous radical surgery (yes,
38%; no, 23%). Keeping these last variables together with the age
grouping into a logistic regression analysis, no significant
interaction was reported with the activity rate.
Long-term outcome
After a median follow-up of 30 months, 91 (77%) patients had
progressed, and 75 (64%) had died. Besides the already mentioned
three early deaths, two other patients died for a disease- and
treatment-unrelated reason: a 66-year-old man committed suicide
after 4 months from initial treatment, and a 36-year-old patient
affected by insulin-dependent diabetes died of uncontrolled
metabolic coma after 3 months from the start of therapy. Median
PFS was 7.4, 8.0, and 5.3 months, for younger, middle-aged and
elderly patients (log-rank test not significant also when adjusted by
gender). In the multivariate analysis, taking into account all
pretreatment characteristics, the presence of disease-related
symptoms was the only variable significantly associated with a
shorter PFS (P¼0.053), while age group was of borderline
significance (P¼0.099). Survival, which at the Cox analysis
resulted significantly affected by number of disease sites and
previous loss of body weight, was unrelated to the age of patients:
indeed, median OS was 13.4, 15.3, and 13.9 months, respectively,
for the three age groups.
DISCUSSION
In this paper, we have retrospectively reported on a series of
patients affected by advanced colorectal carcinoma, randomly
allocated to receive the IRIFAFU regimen, with the aim to ascertain
whether the safety and activity of this regimen could have been
affected by the age of patients. For this purpose, patients were
divided in three age groups. Apart from sex, other baseline
characteristics were evenly distributed across the three groups.
Considering the occurrence of treatment-related adverse events,
as registered by the investigators, it appeared that severe toxicity
was not greater in elderly as compared with other patients. An
usually uncomplicated neutropenia affected a similar proportion
of patients, regardless of age. Occurrence of severe diarrhoea was
even lower among elderly patients. On the whole, a smaller
proportion of elderly patients suffered from any type of severe
toxicity. However, delays or dose reductions were applied during
the initial treatment more frequently for elderly than for remaining
patients. This apparent discrepancy may be explained by an earlier
onset of side effects in elderly patients. Indeed, dose intensity over
eight cycles was not different across the age groups, which is an
indirect evidence that, with a cautious and tailored approach, our
regimen was feasible also in elderly patients.
As for treatment discontinuation, it is worth noting that no
young patient refused the study treatment, in contrast with four
patients each in the two other groups. This observation may
suggest that, despite toxicity was not more pronounced among
these patients, the subjective perception of treatment-related
physical and/or psychological distress was in these cases no longer
tolerable. At this proposal, we would remember that a mental
depression, which is a common psychiatric syndrome in elderly
subjects, may be even more frequent in cancer patients. The
presence and severity of this syndrome, when not sought and
properly managed by the attending physicians, may adversely
affect the compliance of patients to the anticancer treatment.
Although the results reported here were generated by a
retrospective analysis, which was not powered to reveal significant
differences according to age of patients, we believe meaningful that
the proportion of responders was similar in all age groups. In
addition, while a slightly poorer median PFS was registered for
elderly, no difference at all in OS was noted for these patients as
compared to middle-aged and younger ones. In this respect, a
careful check for the presence of disease-related symptoms, or for
a recent loss of body weight, together with an appropriate
assessment of disease extent, showed a greater prognostic
significance than the ECOG PS score.
Of course, this basically descriptive analysis cannot permit to
draw firm conclusions, but it could help in generating hypotheses
for future studies, in which the clinical benefit for elderly patients
should be prospectively outweighed against the occurrence of side
effects. Indeed, we have to admit that patients aged X70 years were
under-represented also in our trial. Although we may confirm that
all eligible patients were offered to entry into this study, we cannot
exclude a systematic selection bias, due to some reluctance of
attending caregivers in referring elderly patients to cancer centres,
or because of a poor willingness of patients themselves to take part
in a randomised trial, or to undergo chemotherapy at all.
Moreover, in our case series no information was collected about
the number and types of associated diseases, which may adversely
affect the long-term outcome of patients (Extermann et al, 1998;
Yancik et al, 1998). This was mainly due to the lack of a standard
scoring system for co-morbidities in cancer patients (Repetto et al,
2002). Furthermore, a comprehensive geriatric assessment, includ-
ing an evaluation of functional, cognitive and psychological status,
has been strongly recommended for aged patients, in order to
anticipate the acceptance and tolerability of a cytotoxic treatment
(Balducci and Yates, 2000; Kearney et al, 2000; Ko ¨hne et al,
2001).
In conclusion, we suggest that geriatrics and medical oncologists
should tightly cooperate in carefully evaluating elderly colon
cancer patients, in order to identify those who may benefit from
irinotecan plus FU combinations, and excluding patients with
Table 4 Severe (WHO grade X3) toxicity according to age grouping
Age groups (years)
Toxicity WHO grade X3 p54 n¼37 55–69 n¼64 X70 n¼17
Neutropenia 43 41 31
Anaemia 0 2 6
Thrombocytopenia 0 3 6
Neutropenic fever/infection 5 3 0
Diarrhoea 11 18 6
Stomatitis 3 2 6
Nausea/vomiting 5 0 6
Alopecia 51 36 12
Hepatic 0 2 0
Cholinergic syndrome 2 1
Any type (except for alopecia) 68 70 50
Numbers are percent of patients.
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lmedical contraindications, or with an impairment of their physical,
cognitive and/or psychological status. Furthermore, we strongly
recommend the implementation of prospective trials to assess
properly the quality of life of elderly patients undergoing
chemotherapy. In this way, it could be possible to counteract an
unjustified ‘ageism’, a prejudice that denies opportunities of
treatment or even cure for patients that, as far as we know, may
have the same chance as younger people (Potosky et al, 2002).
Apart from the obvious ethical and juridical implications of such a
negative attitude, we would remember that a recent economic
evaluation of healthcare intervention has quantified an additional
yearly cost of about $1200 for elderly cancer patients receiving
specific treatments (Hayman et al, 2001). In our opinion, this extra
expense is by far included in the costs that a developed country can
effort to manage these individuals.
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